Potential radiopharmaceuticals for the detection of ocular melanoma. Part II. Iodoquinoline derivatives and...

Area of Science:

• Nuclear medicine
• Radiopharmaceutical research
• Oncology

Background:

• Investigating novel radiotracers for melanoma detection.
• Evaluating the efficacy of iodinated quinolines and Gallium-67 citrate in vivo.
• Assessing tumor uptake and distribution characteristics.

Purpose of the Study:

• To evaluate 4-(substituted amino)-iodoquinolines, including 4-(dimethylamino-ethylamino)-7-iodoquinoline (NM113), as potential radiopharmaceuticals for ocular scintigraphy.
• To compare the tumor uptake of NM113 with 67Ga-citrate in Syrian golden hamsters bearing Greene melanomas.
• To determine the suitability of NM113 labeled with 123I for clinical application.

Main Methods:

• In vivo uptake and distribution studies of 131I-labeled 4-(substituted amino)-iodoquinolines and 67Ga-citrate in hamsters with Greene melanomas.
• In vitro experiments to assess melanin affinity.
• Pharmacological pretreatment variations to influence tracer uptake.

Main Results:

• NM113 demonstrated melanoma uptake (tumor/eye ratio 8.9) but this was found to be incidental.
• In vitro melanin affinity negatively impacted NM113 tumor-to-eye ratios.
• 67Ga-citrate exhibited a significantly higher tumor-to-eye ratio (44.8 at 24 hours) compared to NM113.

Conclusions:

• While NM113 showed initial promise for ocular scintigraphy, its incidental uptake and affinity for melanin limit its clinical utility.
• 67Ga-citrate presents a more promising alternative for patient studies due to its superior tumor-to-eye ratio.
• Further research into NM113's properties did not yield a viable radiopharmaceutical for this application.